<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634283</url>
  </required_header>
  <id_info>
    <org_study_id>07-10-051</org_study_id>
    <nct_id>NCT00634283</nct_id>
  </id_info>
  <brief_title>Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects</brief_title>
  <official_title>Physiologic Monitoring of Antidepressant Medication Effects in Normal Healthy Subjects II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effects of an antidepressant medication and placebo on the brain
      functioning of normal subjects. In this study, recordings of brain electrical activity are
      being used to detect and monitor the response to treatment with venlafaxine IR (Effexor), a
      drug used for the treatment of depression. The intent of this study is to test specific
      hypotheses regarding:

        1. long-term brain effects of a single course of antidepressant treatment

        2. pharmaco-conditioning effects underlying antidepressant tolerance/sensitization

        3. brain functional response to initial versus subsequent antidepressant trials in normal
           healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major Depressive Disorder (MDD) is a lifelong and recurrent illness, such that many
      individuals require multiple courses of antidepressant medication treatment. While some
      patients respond completely to each course of treatment, many do not, and with each
      unsuccessful antidepressant trial the likelihood that a patient will respond decreases. This
      raises the possibility that neurophysiologic response in subsequent antidepressant treatment
      may be influenced by learning processes including sensitization, habituation, and/or
      classical conditioning. Classical conditioning would entail the association of cues such as
      pill-taking (conditioned stimuli; CS) with the effects of active medication (unconditioned
      stimulus; US), such that later presentation of the CS alone would come to elicit a
      conditioned response (CR). Such effects could be revealed by blinded administration of
      placebo following a period of treatment with active medication. Habituation effects
      (tolerance), or sensitization effects (increased response), which require only repeated
      exposure to a stimulus, might be evidenced after repeated courses of antidepressant
      treatment. Knowledge of how learning processes impact neurophysiologic response to successive
      courses of antidepressant treatment would have relevance for clinical populations. Specific
      hypotheses, however, may be tested in healthy non-clinical samples to avoid potential
      confounding factors related to severity or chronicity of illness. Learning theories would
      suggest two hypotheses: (1) neurophysiologic response to placebo will differ between subjects
      who were previously treated with antidepressant treatment as compared to placebo (classical
      conditioning hypothesis); and (2) neurophysiologic response to an initial course of
      antidepressant treatment will differ from response to a repeated course of antidepressant
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects are assigned to one of two groups (antidepressant-experienced and antidepressant-naive) and receive parallel treatment (1 week of placebo followed by 4 weeks of venlafaxine) for the duration of the study. Subjects and assessors were blinded to treatment condition.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>We compared EEG outcomes for those subjects who had been randomly assigned to blinded treatment with venlafaxine (antidepressant-experienced, n=2) vs. placebo (antidepressant-naive, n=4). All subjects received 1 week of placebo followed by 4 weeks of venlafaxine. Subjects were blinded to the treatment during both phases of the study using lookalike capsules. Outcomes assessors and the treating physician also were blinded to treatment condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over Time (4 Weeks).</measure>
    <time_frame>Average over 4 weeks</time_frame>
    <description>Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance &quot;intensity&quot; value, Z, for each electrode in each frequency band where Z(s,f) = Anorm(s,f) + Rnorm(s,f). Analyses for this report focused on changes-from-baseline theta-band (8-12Hz) cordance in the prefrontal region (electrodes Fp1, Fpz, Fp2). Results are defined in terms of positive and negative change where a positive change represents an increased physiologic and behavioral response to the drug (sensitization) and a negative change represents an increased tolerance to the drug (habituation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over 1 Week Placebo lead-in.</measure>
    <time_frame>1-week placebo lead-in</time_frame>
    <description>Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance &quot;intensity&quot; value, Z, for each electrode in each frequency band where Z(s,f) = Anorm(s,f) + Rnorm(s,f). Analyses for this report focused on changes-from-baseline theta-band (8-12Hz) cordance in the prefrontal region (electrodes Fp1, Fpz, Fp2). Results are defined in terms of positive and negative change where a positive change represents an increased physiologic and behavioral response to the drug (sensitization) and a negative change represents an increased tolerance to the drug (habituation).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>antidepressant-experienced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had previously been exposed to active antidepressant medication (venlafaxine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antidepressant-naive</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
    <description>venlafaxine IR 150mg</description>
    <arm_group_label>antidepressant-experienced</arm_group_label>
    <arm_group_label>antidepressant-naive</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject age is 18-75 years

          -  Subject must be in overall good health (i.e., free of any medical condition known to
             affect brain function).

          -  Subject must have participated in former study, Physiologic Monitoring of
             Antidepressant Medication Effects in Normal Controls Subjects (IRB#: 00-11-038-13)

          -  Subject has had a normal physical exam within one year prior to entry of the study

          -  Capacity to give Informed Consent

        Exclusion Criteria:

          -  Subject has serious medical illness, such as high blood pressure, heart disease, renal
             impairment, or cirrhosis of the liver.

          -  Subject meets DSM-IV Axis I criteria for a mood, anxiety, cognitive, or psychiatric
             disorder; or meets criteria for cluster A or B axis II diagnoses. These disorders will
             be determined on the basis of a structured assessment with the MINI (Mini
             International Neuropsychiatric Interview for DSM-IV Axis I Disorders)

          -  Subject has a history of current or past active suicidal ideation or suicide attempts.

          -  Subject has received treatment with an antidepressant medication or any medications
             that could influence brain function since his/her participation in the initial study

          -  Subject is using any of the following medications which interfere with EEG measures of
             brain function: Anticholinergics, Barbiturates, Benzodiazepines, Sedating
             Antihistamines (e.g. diphenhydramine (Benadryl) would be exclusionary, but not
             loratadine (Claritin))

          -  Subject has a history of seizures, brain surgery, skull fracture, significant head
             trauma, or previous abnormal EEG

          -  Subject is pregnant or planning on becoming pregnancy during course of the study

          -  Subject is a UCLA student or staff member directly under instruction or employment of
             any of the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Leuchter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hunter AM, Cook IA, Abrams M, Leuchter AF. Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes? Med Hypotheses. 2013 Dec;81(6):1004-11. doi: 10.1016/j.mehy.2013.09.016. Epub 2013 Sep 17.</citation>
    <PMID>24112999</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>February 4, 2013</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2020</results_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Andrew F. Leuchter</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All 142 research subjects were enrolled at the Laboratory of Brain, Behavior and Pharmacology from 8/19/05-9/30/08.</recruitment_details>
      <pre_assignment_details>Subjects were required to wash out from any exclusionary medication for at least two weeks. Subjects taking fluoxetine were required to wash out for at least 30 days prior to treatment assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Venlafaxine IR (Effexor)</title>
          <description>Five weeks of treatment with venlafaxine IR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Venlafaxine IR (Effexor)</title>
          <description>Five weeks of treatment with venlafaxine IR</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>18 years to 65 years of age. Must be in good health (i.e., free of any medical condition known to affect brain function).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Participants must be 18-75 years old, in overall good health, must have participated in the former study Physiologic Monitoring of Antidepressant Medication Effects in Normal Controls Subjects, has had a normal physical exam one year prior to entry of the study, has the capacity to give informed consent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over Time (4 Weeks).</title>
        <description>Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance &quot;intensity&quot; value, Z, for each electrode in each frequency band where Z(s,f) = Anorm(s,f) + Rnorm(s,f). Analyses for this report focused on changes-from-baseline theta-band (8-12Hz) cordance in the prefrontal region (electrodes Fp1, Fpz, Fp2). Results are defined in terms of positive and negative change where a positive change represents an increased physiologic and behavioral response to the drug (sensitization) and a negative change represents an increased tolerance to the drug (habituation).</description>
        <time_frame>Average over 4 weeks</time_frame>
        <population>Antidepressant-experienced subjects; n=2 and antidepressant-naive subjects; n=4</population>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant Treatment-experienced</title>
            <description>Subjects in this group had prior exposures to antidepressant medication (venlafaxine)</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant Treatment-naive</title>
            <description>Subjects in this group had never before been exposed to antidepressant medication</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over Time (4 Weeks).</title>
          <description>Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance &quot;intensity&quot; value, Z, for each electrode in each frequency band where Z(s,f) = Anorm(s,f) + Rnorm(s,f). Analyses for this report focused on changes-from-baseline theta-band (8-12Hz) cordance in the prefrontal region (electrodes Fp1, Fpz, Fp2). Results are defined in terms of positive and negative change where a positive change represents an increased physiologic and behavioral response to the drug (sensitization) and a negative change represents an increased tolerance to the drug (habituation).</description>
          <population>Antidepressant-experienced subjects; n=2 and antidepressant-naive subjects; n=4</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PFC change after placebo lead-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.44"/>
                    <measurement group_id="O2" value="-0.09" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFC at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.86"/>
                    <measurement group_id="O2" value="-0.88" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PFC over the one-week placebo lead-in period was compared between antidepressant-experienced and antidepressant-naive groups using a between groups t-test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <p_value_desc>The a priori threshold was set at 0.05, 2-tailed, without adjustment for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
            <other_analysis_desc>Group differences in PFC changes over time during administration of venlafaxine were assessed using mixed-model analysis.
we compared brain functional changes over the course of venlafaxine treatment between antidepressant-experienced and antidepressant-na√Øve subjects using linear mixed model analysis (random intercept model) conducted using full maximum likelihood estimation (MLE). Changes in PFC were calculated from the end of placebo lead-in to 48 hours, and 1, 2, and 4 weeks, yielding a within-group factor of time with four levels. We employed a first-order autoregressive covariance structure to reflect our assumption that PFC measurements closer together in time would be more highly correlated.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over 1 Week Placebo lead-in.</title>
        <description>Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance &quot;intensity&quot; value, Z, for each electrode in each frequency band where Z(s,f) = Anorm(s,f) + Rnorm(s,f). Analyses for this report focused on changes-from-baseline theta-band (8-12Hz) cordance in the prefrontal region (electrodes Fp1, Fpz, Fp2). Results are defined in terms of positive and negative change where a positive change represents an increased physiologic and behavioral response to the drug (sensitization) and a negative change represents an increased tolerance to the drug (habituation).</description>
        <time_frame>1-week placebo lead-in</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant Treatment-experienced</title>
            <description>Subjects in this group had prior exposures to antidepressant medication (venlafaxine)</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant Treatment-naive</title>
            <description>Subjects in this group had never before been exposed to antidepressant medication</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over 1 Week Placebo lead-in.</title>
          <description>Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance &quot;intensity&quot; value, Z, for each electrode in each frequency band where Z(s,f) = Anorm(s,f) + Rnorm(s,f). Analyses for this report focused on changes-from-baseline theta-band (8-12Hz) cordance in the prefrontal region (electrodes Fp1, Fpz, Fp2). Results are defined in terms of positive and negative change where a positive change represents an increased physiologic and behavioral response to the drug (sensitization) and a negative change represents an increased tolerance to the drug (habituation).</description>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.44"/>
                    <measurement group_id="O2" value="-0.09" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Antidepressant Treatment-experienced</title>
          <description>Healthy subjects who have been previously exposed to venlafaxine</description>
        </group>
        <group group_id="E2">
          <title>Antidepressant Treatment-naive</title>
          <description>Healthy subjects who have never been previously exposed to antidepressant medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of the Laboratory of Brain</name_or_title>
      <organization>Laboratory of Brain, Behavior, and Pharmacology at UCLA</organization>
      <phone>310-825-0207</phone>
      <email>info@brain.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

